Accurate Risk Stratification in Acute Coronary Syndromes
Faculty: James W. Hoekstra, MD
Format: Digital Newsletter
Credit Available: a maximum of 0.75 AMA PRA Category 1 Credit ™
Course Description: This article is one of three activities available in Med-IQ’s performance improvement series on acute coronary syndromes (ACS). Each of the three articles aligns with one of three designated benchmark areas of improvement: risk stratification, initial pharmacologic management, and time-to-treatment. The online versions of these articles are enhanced with video commentary from expert faculty. This article focuses on the identification and risk stratification of ACS.
Improving Time-to-Treatment in Acute Coronary Syndromes
Faculty: David M. Larson, MD
Format: Digital Newsletter
Credit Available: a maximum of 0.75 AMA PRA Category 1 Credit ™
Course Description: This article is one of three activities available in Med-IQ’s performance improvement series on acute coronary syndromes (ACS). Each of the three articles aligns with one of three designated benchmark areas of improvement: risk stratification, initial pharmacologic management, and time-to-treatment. The online versions of these articles are enhanced with video commentary from expert faculty. This article focuses on reducing time-to-treatment in patients with ACS.
Initial Pharmacologic Management of Acute Coronary Syndromes
Faculty: Christopher P. Cannon, MD
Format: Digital Newsletter
Credit Available: a maximum of 0.75 AMA PRA Category 1 Credit ™
Course Description: This article is one of three activities available in Med-IQ’s performance improvement series on acute coronary syndromes (ACS). Each of the three articles aligns with one of three designated benchmark areas of improvement: risk stratification, initial pharmacologic management, and time-to-treatment. The online versions of these articles are enhanced with video commentary from expert faculty. This article focuses on guidelines-based recommendations for the pharmacologic management of UA/NSTEMI and STEMI.
